A major story in the health sector this week was about an FDA panel removing Avastin as an approved indication, in conjunction with the chemotherapy drug docetaxel, for metastatic (spreading) breast cancer. Well, that’s the major story for the general public. The major story for me was that in Spokane, Washington, agents from the FDA engaged in a legal home…
Read More
